LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Pfizer

Gesloten

SectorGezondheidszorg

27.73 0.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.3

Max

27.93

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.2B

-1.6B

Verkoop

903M

18B

K/W

Sectorgemiddelde

19.89

121.746

EPS

0.66

Dividendrendement

6.32

Winstmarge

-9.387

Werknemers

81,000

EBITDA

-6.6B

-930M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+6.88% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

6.32%

2.26%

Volgende Winsten

28 apr 2026

Volgende dividenddatum

6 mrt 2026

Volgende Ex Dividend datum

8 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.2B

154B

Vorige openingsprijs

27.22

Vorige sluitingsprijs

27.73

Nieuwssentiment

By Acuity

42%

58%

126 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 feb 2026, 12:25 UTC

Winsten

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20 jan 2026, 10:40 UTC

Acquisities, Fusies, Overnames

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 jan 2026, 07:47 UTC

Acquisities, Fusies, Overnames

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

10 feb 2026, 21:51 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:17 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 feb 2026, 21:36 UTC

Winsten

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 19:56 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 19:46 UTC

Winsten

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 17:35 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 17:30 UTC

Winsten

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3 feb 2026, 13:50 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 13:06 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 12:45 UTC

Winsten

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3 feb 2026, 12:02 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 11:48 UTC

Winsten

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3 feb 2026, 11:48 UTC

Winsten

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3 feb 2026, 11:47 UTC

Winsten

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3 feb 2026, 11:46 UTC

Winsten

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer Reaffirms 2026 Guidance >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer 4Q Rev $17.56B >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer 4Q Adj EPS 66c >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer 4Q Loss/Shr 29c >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer 4Q Loss $1.65B >PFE

3 feb 2026, 11:45 UTC

Winsten

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3 feb 2026, 10:41 UTC

Winsten

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

20 jan 2026, 07:13 UTC

Acquisities, Fusies, Overnames

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20 jan 2026, 07:13 UTC

Acquisities, Fusies, Overnames

GSK PLC to Get Special Div of $0.250B

20 jan 2026, 00:21 UTC

Acquisities, Fusies, Overnames

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

6.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.91 USD  6.88%

Hoogste 35.46 USD

Laagste 25 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

6

Buy

12

Hold

0

Sell

Technische score

By Trading Central

22.855 / 23.85Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

126 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat